Novel method for preparing large numbers of foxp3 T regulatory cells for therapeutic suppression of auto immune diseases
- Detailed Technology Description
- Administering a complement antagonist to a naive CD4 T cell substantially inhibits the interaction of C3a or C5a with their respective receptors (C3aR and C5aR) on the CD4 T cell, thereby inducing d
- *Abstract
-
Administering a complement antagonist to a naive CD4 T cell substantially inhibits the interaction of C3a or C5a with their respective receptors (C3aR and C5aR) on the CD4 T cell, thereby inducing differentiation of the naive CD4 T cell into a CD4 FoxP3 Treg cell. This approach efficiently generates FoxP3 Treg cells for use in multiple clinical settings in which attenuating T cell reactivity is beneficial.Examples of T cell mediated diseases include multiple schlerosis, uveitis, bronchial asthma, rheumatoid arthritis, type 1 diabetes, psoriasis, and inflammatory bowel disease.
- Country/Region
- USA
For more information, please click Here
